Full TitleAn Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants with Relapsed or Refractory Multiple Myeloma
The purpose of this study is to assess the safety and effectiveness of combining the drug CC-92480 with dexamethasone and either tazemetostat, BMS-986158, or trametinib in people with multiple myeloma that has come back or continued to grow despite at least three regimens of standard therapy. All of the medications are taken orally (by mouth).
CC-92480 binds to a protein called cereblon, which helps myeloma cells stay alive. Binding to cereblon may cause multiple myeloma cells to die. Dexamethasone is a standard anti-inflammatory drug used to treat people with multiple myeloma. Tazemetostat, BMS-986158, and trametinib all block proteins that may fuel multiple myeloma growth.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- Participants must have multiple myeloma that came back or continued to grow despite at least three regimens of standard therapy.
- Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
- This study is for people age 18 and older.
For more information about this study and to ask about eligibility, please contact the office of Dr. Saad Usmani at 646-608-3757.